Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF). Verona Pharma is currently undertaking a comprehensive Phase 2 clinical trial programme for nebulized RPL554 as a maintenance treatment of COPD and as an add-on therapy to bronchodilators and other commonly used therapies for the treatment of hospitalized patients with acute exacerbations of COPD.

Verona is conducting a clinical study to evaluate the potential of RPL554 as a treatment for cystic fibrosis. RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), that act as both a bronchodilator and an anti-inflammatory agent in a single compound. There is no therapy currently available that acts as both a bronchodilator and anti-inflammatory in a single compound for the treatment of respiratory diseases.